The discovery and status of sibutramine
as an anti-obesity drug

by
Luque CA, Rey JA.
College of Pharmacy,
Nova Southeastern University, 3200 South University Drive,
33328, Fort Lauderdale, FL, USA
Eur J Pharmacol 2002 Apr 12;440(2-3):119-28


ABSTRACT

Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet. Though sibutramine was originally evaluated for possible use as an antidepressant, its research development was eventually redirected to evaluate it as an anorexiant. The pharmacological mechanisms by which sibutramine exerts its weight loss effect are likely due to a combination of reduced appetite, feelings of satiety, and possibly the induction of thermogenesis. Its efficacy for inducing an initial weight-loss and the subsequent maintenance of the weight-loss is well proven in short- and long-term clinical trials of up to 2 years duration. In general, sibutramine has been well tolerated. Increases in blood pressure and heart rate are possible adverse effects that require regular monitoring. Sibutramine is one of the few established and well-proven agents for obesity available for use today and should be considered effective in the management of patients requiring pharmacotherapy as part of the multi-modal approach to weight-loss.
Fen/Phen
Fluoxetine
Sibutramine
Amphetamines
SSRIs and SNRIs
New slimming drugs
Sibutramine compared
Sibutramine for binge-eaters
Sibutramine v dexfenfluramine
Sibutramine as an antidepressant
Sibutramine: clinical pharmacology
Sibutramine (Meridia) for treating obesity



Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family